US Studies Confirm Ability of TRXE-009 to Kill Brain Cancer Stem Cells

-- Potent killing of highly resistant adult and pediatric brain cancer cells
-- Opportunity to effect prevention of recurrence of brain cancer

SYDNEY, March 4, 2015  -- Australian/US biotechnology company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer.

The latest study looked at the ability of TRXE-009 to kill a library of patient-derived cell cultures from subjects with glioblastoma multiform (GBM). The cells were cultured under conditions that promote cancer stem cell growth. These stem-like cancer cells are believed to be responsible for chemotherapy resistance and tumor recurrence.

CorMedix Inc. Provides Multiple Strategic Business Updates

-CorMedix Inc. Engages Evercore as Financial Advisor to Explore Strategic Alternatives to Maximize Shareholder Value-
-Elliott Management Provides Backstop Financing Commitment and Granted Right to Appoint Two Incremental Board Members-
-CorMedix Notified of Compliance with NYSE Listing Requirements-
- Expiration Date Extended for Certain Warrants-
-Will report Fourth Quarter 2014 Results and Host Conference Call on March 13 at 9 am EDT

BEDMINSTER, N.J., March 4, 2015 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced several strategic business updates.

CorMedix Engages Evercore as Financial Advisor to Explore Strategic Alternatives

BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

- BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months -

JERUSALEM-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions required to commence a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML). Due to BL-8040’s unique properties, the Phase 2b study will examine its ability to improve outcomes for AML patients who have achieved remission after standard treatment by eliminating the minimal residual disease left in the bone marrow that can lead to relapse, known as consolidation therapy. The study is expected to commence shortly after the receipt of regulatory approval, which is anticipated in the next few months, and is the first of three additional planned clinical studies that significantly expand BioLineRx’s unique BL-8040 platform for treating hematological cancers.